Articles published by Convergent Therapeutics Inc.

Convergent Therapeutics to Present Phase 2 Results Demonstrating Potent Anti-Tumor Activity of CONV01-α in Lu-PSMA-Naïve Prostate Cancer at ESMO Congress 2026

October 23, 2026

From Convergent Therapeutics Inc.

Via Business Wire

Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)

June 01, 2026

From Convergent Therapeutics Inc.

Via Business Wire

Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026

May 21, 2026

From Convergent Therapeutics Inc.

Via Business Wire

Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer

April 29, 2026

From Convergent Therapeutics Inc.

Via Business Wire

Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting

April 21, 2026

From Convergent Therapeutics Inc.

Via Business Wire

Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors

March 19, 2026

From Convergent Therapeutics Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Convergent Therapeutics Inc.

Starting at /week.